Ferring Pharmaceuticals moves to strengthen growth with appointment of Chief Medical and Chief Scientific officers
Saint-Prex, Switzerland – 27 January 2015 –
Ferring Pharmaceuticals announced today the appointment of Pascal Danglas, MD as Executive Vice President and Chief Medical Officer and Per Falk, MD, PhD as Executive Vice President and Chief Scientific Officer. Both appointments are effective as of 1 February.
“Ferring aims to expand its portfolio and improve patient access to our products,” said Michel Pettigrew, President of the Executive Board and Chief Operating Officer of Ferring. “By focusing our efforts in R&D and patient access under these two proven leaders, Ferring is positioning itself to accelerate growth and better meet patient needs.”
As Chief Medical Officer, Pascal Danglas will evaluate and advise on new product candidates. He will also focus on strengthening patient access to Ferring products as the company’s liaison to the medical community, patients and national reimbursement authorities. An industry veteran, Danglas previously served as executive vice president of clinical and product development with Ferring.
Per Falk joins Ferring as Chief Scientific Officer after a successful assignment as senior vice president responsible for biopharmaceuticals research at Novo Nordisk A/S. In his new role, Falk will be responsible for overseeing the entirety of Ferring’s research and development activities, from basic research through to regulatory approval.
– ENDS –
About Ferring Pharmaceuticals
Headquartered in Saint-Prex, Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology, endocrinology and orthopaedics. Ferring has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.
To learn more about Ferring or its products please visit www.ferring.com.